Yimin Cui
Overview
Explore the profile of Yimin Cui including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
272
Citations
2071
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Fu L, Jia G, Liu Z, Pang X, Cui Y
Acta Pharm Sin B
. 2025 Mar;
15(1):1-14.
PMID: 40041903
Artificial intelligence (AI) has emerged as a transformative force in healthcare, with applications spanning diagnostics to drug development. However, its integration into drug regulation remains nascent, with varying degrees of...
2.
Yan M, Cui Y, Xiang Q
Theranostics
. 2025 Feb;
15(5):1715-1740.
PMID: 39897543
Chronic liver diseases, primarily metabolic dysfunction-associated steatotic liver disease (MASLD), metabolic and metabolic dysfunction-associated alcoholic liver disease (MetALD), and viral hepatitis, can lead to liver fibrosis, cirrhosis, and cancer. Hepatic...
3.
Wang G, Zhao K, Zhao X, Cui Y, He P, Zhang T, et al.
Expert Rev Vaccines
. 2025 Jan;
24(1):128-137.
PMID: 39834144
Background: The development of bivalent or multivalent vaccines offers a promising strategy for combating SARS-CoV-2 mutations. Research Design And Methods: In this phase 2 trial, conducted from 1 December 2021,...
4.
Chong S, Sun L, Mu G, Hua M, Xiang Q, Cui Y
Paediatr Drugs
. 2025 Jan;
PMID: 39826085
Background: This study aimed to provide a comprehensive review of adverse events (AEs) associated with factor Xa (FXa) inhibitors in pediatric patients. Methods: We searched PubMed, Embase, Cochrane Library, ClinicalTrials.gov,...
5.
Tang C, Wang H, Guo L, Cui Y, Zou C, Hu J, et al.
ACS Nano
. 2025 Jan;
19(3):3339-3361.
PMID: 39812806
Atherosclerosis (AS) is a prevalent inflammatory vascular disease characterized by plaque formation, primarily composed of foam cells laden with lipids. Despite lipid-lowering therapies, effective plaque clearance remains challenging due to...
6.
Yan M, Wang Z, Qiu Z, Cui Y, Xiang Q
Biomark Res
. 2024 Dec;
12(1):164.
PMID: 39736771
Platelets are essential for blood clotting and maintaining normal hemostasis. In pathological conditions, platelets are increasingly recognized as crucial regulatory factors in various immune-mediated inflammatory diseases. Resting platelets are induced...
7.
Wang A, Du Q, Li X, Cui Y, Luo J, Li C, et al.
Metabolites
. 2024 Dec;
14(12).
PMID: 39728476
Background: is a member of the lactic acid bacterium group commonly found in many salt-fermented foods. Strains of isolated from high-salinity environments have been shown to tolerate salt stress to...
8.
Lyu C, He Z, Hu X, Wang S, Qin M, Zhu L, et al.
Nat Commun
. 2024 Nov;
15(1):10155.
PMID: 39578473
The binding of viruses to host-entry factor receptors is an essential step for viral infection. Many studies have shown that macrophages can internalize viruses and degrade them in lysosomes for...
9.
Sun X, Zhang J, Dong B, Xiong Q, Wang X, Gu Y, et al.
Adv Sci (Weinh)
. 2024 Nov;
12(1):e2400367.
PMID: 39499724
Liver metastasis is the major cause of death in colorectal cancer (CRC) due to the lack of effective treatment. To explore novel drivers of CRC liver metastasis, the transcriptomes of...
10.
Mu G, Liu Y, Xie Q, Liu Z, Zhang H, Meng X, et al.
Curr Pharm Des
. 2024 Oct;
PMID: 39449344
Aims: To improve the understanding of pharmacokinetic/pharmacodynamic (PK/PD) profiles of apixaban, supporting personalised drug prescriptions for future patients. Background: Genetic as well as nongenetic factors can affect the predictable PK...